Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/42367
Título: Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)
Autores/as: Wägner, A. M. 
Miranda Calderín, Guillermo 
Ugarte-Lopetegui, M. A.
Marrero-Santiago, H.
Suárez-Castellano, L.
López-Madrazo, M. J.
Alberiche-Ruano, M. P.
Abselam Ahmed, N.
Alemán, C.
Castellot-Martín, A.
Díez del Pino, A.
Nóvoa-Mogollón, F. J.
Clasificación UNESCO: 32 Ciencias médicas
Palabras clave: Diabetes
Ergometry
GLP-1 agonist
Maximum oxygen consumption
Randomized controlled trial, et al.
Fecha de publicación: 2019
Editor/a: 1262-3636
Publicación seriada: Diabetes and Metabolism 
Resumen: Aims To assess the effect of the GLP-1 analogue liraglutide on measures of cardiac function and physical performance in patients with type 2 diabetes (T2D). Methods In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7–10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liraglutide 1.8 mg/day or a placebo for 6 months. The primary endpoint was maximum oxygen consumption (VO2max) during cycle ergometry, while other procedures included a 6-min walk test, echocardiography, anthropometry and blood tests. Safety endpoints were also monitored, and an intention-to-treat analysis was performed. Results A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo. There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months. HbA1c was lower (6.7% vs. 7.7%; P =  0.005), with a trend towards lower maximum systolic blood pressure during ergometry [171.7 (24.4) vs. 192.5 (25.6); P = 0.052] in the liraglutide group at the end of the study. There were no severe adverse events. Conclusion In this trial, liraglutide improved glycaemic control in T2D, but had no significant effects on either physical performance or myocardial function.
URI: http://hdl.handle.net/10553/42367
ISSN: 1262-3636
DOI: 10.1016/j.diabet.2018.08.010
Fuente: Diabetes & Metabolism[ISSN 1262-3636],v. 45 (3), p. 268-275, (Junio 2019)
Colección:Artículos
Vista completa

Citas SCOPUSTM   

17
actualizado el 10-nov-2024

Citas de WEB OF SCIENCETM
Citations

15
actualizado el 10-nov-2024

Visitas

172
actualizado el 12-oct-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.